Back to results
US 10,144,944 B2Granted
Methods of cell culture
AssigneeMomenta Pharmaceuticals, Inc.
InventorHolly Prentice
Life of this patent
Estimating the term…
Abstract
Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.
Claims23
A method of producing an adalimumab preparation having a target value of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans, the method comprising:
- (a) providing a cell genetically engineered to express adalimumab;
- (b) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab;
- and
- (c) harvesting a preparation of the adalimumab produced by the cell that meets the target value of the one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans,
- wherein the target value of fucosylated glycans, galactosylated glycans, or sialylated glycans is a level at least 10% higher than a level of fucosylated glycans, galactosylated glycans, or sialylated glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine;
- or
- wherein the target value of high mannose glycans is a level at least 10% lower than a level of high mannose glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine.
4 more elements
A method of producing an adalimumab preparation, the method comprising:
- (a) providing a target value of one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans;
- (b) providing a cell genetically engineered to express adalimumab;
- (c) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab;
- (d) harvesting a preparation of the adalimumab produced by the cell;
- and
- (e) formulating the adalimumab preparation into a drug product if the adalimumab preparation meets the target value of the one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans;
- wherein the target value of fucosylated glycans, galactosylated glycans, or sialylated glycans is a level at least 10% higher than a level of fucosylated glycans, galactosylated glycans, or sialylated glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine;
- or
- wherein the target value of high mannose glycans is a level at least 10% lower than a level of high mannose glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine.
6 more elements
A method of increasing a level of one or more of fucosylated glycans, galactosylated glycans and sialylated glycans in an adalimumab preparation, the method comprising:
- (a) providing a cell genetically engineered to express adalimumab;
- (b) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab;
- and
- (c) harvesting a preparation of adalimumab produced by the cell, wherein the adalimumab preparation has a level of one or more of fucosylated glycans, galactosylated glycans and sialylated glycans that is at least 10% higher than a level of one or more of fucosylated glycans, galactosylated glycans and sialylated glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine.
1 more element
A method of decreasing a level of one or more high mannose glycans in an adalimumab preparation, the method comprising:
- (a) providing a cell genetically engineered to express adalimumab;
- (b) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab;
- and
- (c) harvesting a preparation of the adalimumab produced by the cell, wherein the adalimumab preparation has a level of high mannose glycans that is at least 10% lower than a level of high mannose glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine.
1 more element
Dependencies are inferred from the claim text.